Verona Pharma PLC Change of Registered Office

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                          Change in Registered Office 
 
19 April 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
today announces that its registered office address has changed to: One Central 
Square, Cardiff, CF10 1FS. 
 
For further information, please contact: 
 
Verona Pharma plc                      Tel: +44 (0)20 7863 3300 
Jan-Anders Karlsson, CEO 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
Simon Conway / Julia Phillips 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
2 trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  In addition, 
the Company is exploring the potential of the drug in different diseases, such 
as cystic fibrosis, where it is in pre-clinical testing and has received a 
Venture and Innovation Award from the UK Cystic Fibrosis Trust. 
 
 
 
END

(END) Dow Jones Newswires

April 19, 2016 10:16 ET (14:16 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024